RDEA3170 and Febuxostat Combination Study in Gout Subjects
NCT02246673
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Gout
Interventions
DRUG:
RDEA3170 15 mg
DRUG:
RDEA3170 10 mg
DRUG:
RDEA3170 2.5
DRUG:
RDEA3170 5 mg
DRUG:
Febuxostat 40 mg
DRUG:
Febuxostat 80 mg
Sponsor
Ardea Biosciences, Inc.